Opus Genetics (NASDAQ:IRD – Get Free Report) is expected to announce its Q3 2026 results before the market opens on Wednesday, November 11th. Analysts expect Opus Genetics to announce earnings of ($0.14) per share and revenue of $1.55 million for the quarter. Parties may review the information on the company’s upcoming Q3 2026 earnings report for the latest details on the call scheduled for Thursday, November 19, 2026 at 12:30 PM ET.
Opus Genetics Stock Up 0.5%
Shares of Opus Genetics stock opened at $4.20 on Tuesday. The business has a fifty day simple moving average of $4.48 and a two-hundred day simple moving average of $4.21. Opus Genetics has a 1 year low of $1.70 and a 1 year high of $7.07.
Wall Street Analysts Forecast Growth
Several research firms have commented on IRD. BTIG Research reiterated a “buy” rating and issued a $12.00 price objective on shares of Opus Genetics in a report on Wednesday, September 9th. Zacks Research upgraded shares of Opus Genetics from a “strong sell” rating to a “hold” rating in a research note on Tuesday, August 11th. Chardan Capital restated a “buy” rating and set a $16.00 target price on shares of Opus Genetics in a research note on Thursday, October 22nd. HC Wainwright reaffirmed a “buy” rating and set a $8.00 target price on shares of Opus Genetics in a report on Wednesday, September 9th. Finally, Citizens Jmp reiterated a “market outperform” rating and issued a $17.00 price target on shares of Opus Genetics in a research note on Friday, October 16th. One equities research analyst has rated the stock with a Strong Buy rating, sixteen have issued a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, the stock has an average rating of “Moderate Buy” and an average target price of $12.71.
Insider Transactions at Opus Genetics
In related news, Director Fighting Blindness Foundation sold 556,000 shares of the company’s stock in a transaction dated Wednesday, September 30th. The shares were sold at an average price of $4.96, for a total value of $2,757,760.00. Following the transaction, the director directly owned 3,236,171 shares in the company, valued at approximately $16,051,408.16. This represents a 14.66% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, CEO George Magrath sold 28,258 shares of the firm’s stock in a transaction dated Tuesday, November 3rd. The stock was sold at an average price of $3.90, for a total transaction of $110,206.20. Following the transaction, the chief executive officer directly owned 2,010,636 shares in the company, valued at approximately $7,841,480.40. This represents a 1.39% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders sold a total of 673,805 shares of company stock worth $3,213,582 over the last ninety days. Corporate insiders own 11.70% of the company’s stock.
About Opus Genetics
Opus Genetics, Inc is a clinical-stage biotechnology company focused on developing gene therapies for inherited retinal diseases (IRDs), a group of rare genetic disorders that can cause progressive vision loss and blindness. The company’s research is aimed at addressing the underlying genetic causes of these conditions rather than treating only their symptoms.
Its pipeline includes investigational ophthalmic gene therapies designed for specific IRD-causing mutations, including programs targeting conditions associated with the NR2E3 and BEST1 genes.
Featured Articles
- Five stocks we like better than Opus Genetics
- Wall Street May Be Making a Big Mistake With monday.com Stock
- Are These 2 Mid-Cap Growth Stocks Worth the Risk?
- Oklo Changes the Narrative: Does a Nuclear Stock Price Explosion Come Next?
- Cloudflare’s 20% Sell-Off May Have Created an Opening for Investors
Receive News & Ratings for Opus Genetics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Opus Genetics and related companies with MarketBeat.com's FREE daily email newsletter.
